Clermont-Ferrand (France) and Indianapolis (United-States), January 10, 2017 - Cyclopharma today announced that its Board has approved a change in the company’s US leadership. Peter Webner is appointed as CEO of Cyclopharma US Corp, effective Jan. 1st, 2018, while Bernard Landes will remain Chairman of the Board.

Peter Webner will drive the development of Cyclopharma’s pipeline of new companion diagnostic PET tracers for oncology in the US. His first objective will be to ensure EstroTep’s US FDA submission and approval and access to the US market by the end of 2019. EstroTep is a PET tracer approved for use in France which is indicated in metastatic breast cancer.

"I am honored to take on the challenge of building a US division for Cyclopharma. The immediate task at hand is getting EstroTep filed with the FDA and making it available upon approval", said Peter. "Cyclopharma has a history of investing in novel targeted companion diagnostics that are valuable in guiding clinical decision making. The company has a solid pipeline of products and clinical targets which will be launched in the future. We believe in a bright future for Molecular Imaging and look forward to providing additional diagnostic tools to use."
Bernard commented "We are very pleased to have Peter join the team. As our first US based employee he brings a considerable and complementary experience to the Cyclopharma team that will enable us to accelerate our US development plans while actively contributing to building our pipeline of companion diagnostic PET tracers for oncology."

Peter Webner was Senior Vice President, Manufacturing and Sales for Zevacor Molecular and Interim Executive Vice President for Zevacor Pharma. A certified nuclear medicine technologist, Mr. Webner has over 25 years of experience in nuclear medicine and molecular imaging, focused on with a wide range of responsibilities. Building on clinical and administrative experience gained at Mt. Sinai Medical Center in New York, he has held key positions in sales, marketing, product development and management with Eastern Isotopes, IBA Molecular, Positron Corporation, NCM, and Zevacor Molecular and Zevacor Pharma. Mr. Webner earned his BA in Radiological Health Sciences at Manhattan College and completed advanced studies in product development at the Harvard Graduate School of Business.


About Cyclopharma
Since its creation in 2000, Cyclopharma has developed molecular imaging solutions to allow the observation of cell function in vivo as part of the targeted treatment of cancer, in order to improve individualized treatment plans for patients in terms of diagnostics, monitoring and therapeutic effectiveness, whilst also reducing costs.

With more than 120 employees and revenue of €23 million, Cyclopharma invests more than 10% of revenue in research into novel molecular imaging tracers. Since 2015 it has built on dense and balanced geographical coverage to drive international growth, with the aim of becoming a major European force in personalized medicine

Molecular Imaging Homepage